Patents by Inventor Robert Plourde
Robert Plourde has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160323337Abstract: Computer program products, methods, systems, apparatus, and computing entities are provided for sessions with participants and providers. For example, in one embodiment, a provider can interact with multiple participants to conduct interactive treatment sessions. Further, a participant can interact with multiple providers to conduct interactive treatment sessions. For the interactive treatment sessions, motion data and video data of the participant can be simultaneously displayed to the provider.Type: ApplicationFiled: March 31, 2016Publication date: November 3, 2016Inventors: Brian R. Landwehr, CULLEN DAVIS, SANDY JOHNSON, ARRIANNE HOYLAND, SHANE HUSTON, DAVID KAMINSKI, ROBERT PLOURDE, TIMOTHY ARNAL, ANDREW CHESTER
-
Patent number: 9306999Abstract: Computer program products, methods, systems, apparatus, and computing entities are provided for sessions with participants and providers. For example, in one embodiment, a provider can interact with multiple participants to conduct interactive treatment sessions. Further, a participant can interact with multiple providers to conduct interactive treatment sessions. For the interactive treatment sessions, motion data and video data of the participant can be simultaneously displayed to the provider.Type: GrantFiled: June 7, 2013Date of Patent: April 5, 2016Assignee: UNITEDHEALTH GROUP INCORPORATEDInventors: Brian R. Landwehr, Cullen Davis, Sandy Johnson, Arrianne Hoyland, Shane Huston, David Kaminski, Robert Plourde, Timothy Arnal, Andrew Chester
-
Publication number: 20130332616Abstract: Computer program products, methods, systems, apparatus, and computing entities are provided for sessions with participants and providers. For example, in one embodiment, a provider can interact with multiple participants to conduct interactive treatment sessions. Further, a participant can interact with multiple providers to conduct interactive treatment sessions. For the interactive treatment sessions, motion data and video data of the participant can be simultaneously displayed to the provider.Type: ApplicationFiled: June 7, 2013Publication date: December 12, 2013Inventors: BRIAN R. LANDWEHR, CULLEN DAVIS, SANDY JOHNSON, ARRIANNE HOYLAND, SHANE HUSTON, DAVID KAMINSKI, ROBERT PLOURDE, TIMOTHY ARNAL, ANDREW CHESTER
-
Patent number: 8039465Abstract: The present invention is directed to synthetic cytoskeletal active compounds that are related to natural Latrunculin A or Latrunculin B. The present invention is also directed to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The invention is additionally directed to a method of preventing or treating diseases or conditions associated with actin polymerization. In one embodiment of the invention, the method treats increased intraocular pressure, such as primary open-angle glaucoma. The method comprises administering to a subject a therapeutically effective amount of a cytoskeletal active compound of Formula I or II, wherein said amount is effective to influence the cytoskeleton, for example by inhibiting actin polymerization.Type: GrantFiled: January 28, 2010Date of Patent: October 18, 2011Assignee: Inspire Pharmaceuticals, Inc.Inventors: John W. Lampe, Robert Plourde, Jr., Jin She, Jason L. Vittitow, Paul S. Watson, Michael T. Crimmins, David J. Slade
-
Patent number: 7943760Abstract: This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a non-nucleotide compound, preferably a P2Y12 receptor antagonist compound, wherein said amount is effective to inhibit platelet aggregation. The compounds useful for this invention include compounds of general Formulae I and III-XII, or salts, hydrates, and solvates thereof. The present invention also provides novel compounds of Formulae I and III-XII.Type: GrantFiled: September 2, 2009Date of Patent: May 17, 2011Assignee: Inspire Pharmaceuticals, Inc.Inventors: Robert Plourde, Jr., Sammy R. Shaver, James G. Douglass, III, Paul S. Watson, José L. Boyer, Chi Tu, Melwyn A. Abreo, Lorenzo J. Alfaro-Lopez, Yangbo Feng, Daniel F. Harvey, Tatyana V. Khasonova
-
Publication number: 20100197913Abstract: This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a non-nucleotide compound, preferably a P2Y12 receptor antagonist compound, wherein said amount is effective to inhibit platelet aggregation. The compounds useful for this invention include compounds of general Formulae I and III-XII, or salts, hydrates, and solvates thereof. The present invention also provides novel compounds of Formulae I and III-XII.Type: ApplicationFiled: September 2, 2009Publication date: August 5, 2010Inventors: Robert Plourde, JR., Sammy R. Shaver, James G. Douglass, III, Paul S. Watson, José L. Boyer, Chi Tu, Melwyn A. Abreo, Lorenzo J. Alfaro-Lopez, Yangbo Feng, Daniel F. Harvey, Tatyana V. Khasonova
-
Patent number: 7749980Abstract: The present invention is directed to a method of treating pain. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a P2X receptor antagonist. The methods of the present invention are useful in reducing pain, such as traumatic pain, neuropathic pain, organ pain and/or pain associated with diseases. The P2X receptor antagonists useful for this invention are non-nucleotide compounds of general Formula I. Compounds of Formula I can be used alone to treat pain. Compounds of Formula I can also be used in conjunction with other therapeutic agents or adjunctive therapies commonly used to treat pain, thus enhancing the therapeutic effect of pain reduction.Type: GrantFiled: October 21, 2004Date of Patent: July 6, 2010Assignee: Inspire Pharmaceuticals, Inc.Inventors: Robert Plourde, Jr., Sammy R. Shaver, Melwyn Anthony Abreo, Lorenzo Josue Alfaro-Lopez, Yangbo Feng, Tatyana V. Khasanova, Mark W. Holladay, Christopher S. Crean
-
Publication number: 20100130572Abstract: The present invention is directed to synthetic cytoskeletal active compounds that are related to natural Latrunculin A or Latrunculin B. The present invention is also directed to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The invention is additionally directed to a method of preventing or treating diseases or conditions associated with actin polymerization. In one embodiment of the invention, the method treats increased intraocular pressure, such as primary open-angle glaucoma. The method comprises administering to a subject a therapeutically effective amount of a cytoskeletal active compound of Formula I or II, wherein said amount is effective to influence the cytoskeleton, for example by inhibiting actin polymerization.Type: ApplicationFiled: January 28, 2010Publication date: May 27, 2010Inventors: John W. LAMPE, Robert Plourde, JR., Jin She, Jason L. Vittitow, Paul S. Watson, Michael T. Crimmins, David J. Slade
-
Patent number: 7666861Abstract: The present invention is directed to synthetic cytoskeletal active compounds that are related to natural Latrunculin A or Latrunculin B. The present invention is also directed to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The invention is additionally directed to a method of preventing or treating diseases or conditions associated with actin polymerization. In one embodiment of the invention, the method treats increased intraocular pressure, such as primary open-angle glaucoma. The method comprises administering to a subject a therapeutically effective amount of a cytoskeletal active compound of Formula I or II, wherein said amount is effective to influence the cytoskeleton, for example by inhibiting actin polymerization.Type: GrantFiled: December 4, 2007Date of Patent: February 23, 2010Assignee: Inspire Pharmaceuticals, Inc.Inventors: John W. Lampe, Robert Plourde, Jr., Jin She, Jason L. Vittitow, Paul S. Watson, Michael T. Crimmins, David J. Slade
-
Patent number: 7592445Abstract: This invention is directed to compounds of Formulae III and V, useful for treating diseases or conditions associated with platelet aggregation.Type: GrantFiled: January 4, 2008Date of Patent: September 22, 2009Assignee: Inspire Pharmaceuticals, Inc.Inventors: Robert Plourde, Jr., Sammy R. Shaver, James G. Douglass, III, Paul S. Watson, José L. Boyer, Chi Tu, Melwyn A. Abreo, Lorenzo J. Alfaro-Lopez, Yangbo Feng, Daniel F. Harvey, Tatyana V. Khasonova
-
Patent number: 7368438Abstract: This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a non-nucleotide compound, preferably a P2Y12 receptor antagonist compound, wherein said amount is effective to inhibit platelet aggregation. The compounds useful for this invention include compounds of general Formula I and III-XI, or salts, hydrates, and solvates thereof. The present invention also provides novel compounds according to Formula I and III-XI.Type: GrantFiled: October 21, 2004Date of Patent: May 6, 2008Assignee: Inspire Pharmaceuticals, Inc.Inventors: Robert Plourde, Jr., Sammy R. Shaver, José L. Boyer, Melwyn A. Abreo, Lorenzo J. Alfaro-Lopez, Yangbo Feng, Daniel F. Harvey, Tatyana V. Khasonova, Chi Tu
-
Publication number: 20080103304Abstract: This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a non-nucleotide compound, preferably a P2Y12 receptor antagonist compound, wherein said amount is effective to inhibit platelet aggregation. The compounds useful for this invention include compounds of general Formulae I and III-XII, or salts, hydrates, and solvates thereof. The present invention also provides novel compounds of Formulae I and III-XII.Type: ApplicationFiled: January 4, 2008Publication date: May 1, 2008Inventors: Robert Plourde, Sammy Shaver, James Douglass, Paul Watson, Jose Boyer, Chi Tu, Melwyn Abreo, Lorenzo Alfaro-Lopez, Yangbo Feng, Daniel Harvey, Tatyana Khasonova
-
Publication number: 20080076735Abstract: The present invention is directed to synthetic cytoskeletal active compounds that are related to natural Latrunculin A or Latrunculin B. The present invention is also directed to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The invention is additionally directed to a method of preventing or treating diseases or conditions associated with actin polymerization. In one embodiment of the invention, the method treats increased intraocular pressure, such as primary open-angle glaucoma. The method comprises administering to a subject a therapeutically effective amount of a cytoskeletal active compound of Formula I or II, wherein said amount is effective to influence the cytoskeleton, for example by inhibiting actin polymerization.Type: ApplicationFiled: December 4, 2007Publication date: March 27, 2008Inventors: John Lampe, Robert Plourde, Jin She, Jason Vittitow, Paul Watson, Michael Crimmins, David Slade
-
Patent number: 7335648Abstract: This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a compounds useful for this invention include compounds of general Formulae I and III-XII, or salts, hydrates, and solvates thereof. The present invention also provides novel compounds of Formulae I and III-XII.Type: GrantFiled: May 5, 2005Date of Patent: February 26, 2008Assignee: Inspire Pharmaceuticals, Inc.Inventors: Robert Plourde, Jr., Sammy R. Shaver, James G. Douglass, III, Paul S. Watson, José L. Boyer, Chi Tu, Melwyn A. Abreo, Lorenzo J. Alfaro-Lopez, Yangbo Feng, Daniel F. Harvey, Tatyana V. Khasonova
-
Patent number: 7320974Abstract: The present invention is directed to synthetic cytoskeletal active compounds that are related to natural Latrunculin A or Latrunculin B. The present invention is also directed to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The invention is additionally directed to a method of preventing or treating diseases or conditions associated with actin polymerization. In one embodiment of the invention, the method treats increased intraocular pressure, such as primary open-angle glaucoma. The method comprises administering to a subject a therapeutically effective amount of a cytoskeletal active compound of Formula I or II, wherein said amount is effective to influence the cytoskeleton, for example by inhibiting actin polymerization.Type: GrantFiled: March 23, 2006Date of Patent: January 22, 2008Assignee: Inspire Pharmaceuticals, Inc.Inventors: John W. Lampe, Robert Plourde, Jr., Jin She, Jason L. Vittitow, Paul S. Watson, Michael T. Crimmins, David J. Slade
-
Publication number: 20070123544Abstract: The present invention is directed to a method of treating pain. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a P2X receptor antagonist. The methods of the present invention are useful in reducing pain, such as traumatic pain, neuropathic pain, organ pain and/or pain associated with diseases. The P2X receptor antagonists useful for this invention are non-nucleotide compounds of general Formula I. Compounds of Formula I can be used alone to treat pain. Compounds of Formula I can also be used in conjunction with other therapeutic agents or adjunctive therapies commonly used to treat pain, thus enhancing the therapeutic effect of pain reduction.Type: ApplicationFiled: October 21, 2004Publication date: May 31, 2007Inventors: Robert Plourde, Sammy Shaver, Melwyn Abreo, Lorenzo Alfaro-Lopez, Yangho Feng, Tatyana Khasanova, Mark Holladay, Christopher Crean
-
Publication number: 20070083417Abstract: A system for enabling real-time collaboration and workflow management of a marketing campaign within a marketing organization is disclosed. In one aspect, user displays for the marketing organization's computer system are provided. A role portal component provides at least two respective role portals that correspond to at least two marketing roles within the marketing organization (for example, marketing executive, marketing manager, data analyst, etc.). A workbench component generates, on a user display, a workbench that corresponds to each of the role portals. Each workbench permits a user to access metric and workflow information associated with the corresponding marketing role. The workbench for each role may comprise several displayable web-pages, such as a home page, an activities page workflow, a marketing campaigns with information and metrics about various marketing campaigns, and a customer analysis page.Type: ApplicationFiled: October 5, 2006Publication date: April 12, 2007Inventors: Todd Wagner, Robert Plourde, J. O'Halloran, George Corugedo, Chuck Tyner
-
Publication number: 20060217427Abstract: The present invention is directed to synthetic cytoskeletal active compounds that are related to natural Latrunculin A or Latrunculin B. The present invention is also directed to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The invention is additionally directed to a method of preventing or treating diseases or conditions associated with actin polymerization. In one embodiment of the invention, the method treats increased intraocular pressure, such as primary open-angle glaucoma. The method comprises administering to a subject a therapeutically effective amount of a cytoskeletal active compound of Formula I or II, wherein said amount is effective to influence the cytoskeleton, for example by inhibiting actin polymerization.Type: ApplicationFiled: March 23, 2006Publication date: September 28, 2006Inventors: John Lampe, Robert Plourde, Jin She, Jason Vittitow, Paul Watson, Michael Crimmins, David Slade
-
Patent number: 7084128Abstract: The present invention is directed to a method of reducing intraocular pressure. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a purinerginic receptor ligand, which is a mononucleoside polyphosphate or dinucleoside polyphosphate defined by general Formula I. The method of the present invention is useful in the treatment or prevention of ocular hypertension, such as glaucoma, including primary and secondary glaucoma. The method can be used alone to reduce intraocular pressure. The method can also be used in conjunction with other therapeutic agents or adjunctive therapy commonly used to treat glaucoma to enhance the therapeutic effect of reducing the intraocular pressure.Type: GrantFiled: January 15, 2003Date of Patent: August 1, 2006Assignee: Inspire Pharmaceuticals, Inc.Inventors: Benjamin R. Yerxa, Robert Plourde, Jr., Edward G. Brown, Ward M. Peterson
-
Publication number: 20050267134Abstract: This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a non-nucleotide compound, preferably a P2Y12 receptor antagonist compound, wherein said amount is effective to inhibit platelet aggregation, preferably in a reversible manner. The compounds useful for this invention include compounds of general Formulae I and III-XII, or salts, hydrates, and solvates thereof. The present invention also provides novel compounds of Formulae I and III-XII.Type: ApplicationFiled: May 5, 2005Publication date: December 1, 2005Inventors: Robert Plourde,, Sammy Shaver, James Douglass,, Paul Watson, Jose Boyer, Chi Tu, Melwyn Abreo, Lorenzo Alfaro-Lopez, Yangbo Feng, Daniel Harvey, Tatyana Khasanova